[
  {
    "ts": null,
    "headline": "Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
    "summary": "Quest Diagnostics Inc (DGX) reports robust financial performance with significant revenue growth and strategic initiatives, setting a positive tone for 2026 despite challenges.",
    "url": "https://finnhub.io/api/news?id=403378093b9e14512af0036492eeacf8e7057fc5569d732fec8850220d361daf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770757344,
      "headline": "Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
      "id": 139036503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics Inc (DGX) reports robust financial performance with significant revenue growth and strategic initiatives, setting a positive tone for 2026 despite challenges.",
      "url": "https://finnhub.io/api/news?id=403378093b9e14512af0036492eeacf8e7057fc5569d732fec8850220d361daf"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Quest (DGX) Stock Soaring Today",
    "summary": "Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX) jumped 6.8% in the afternoon session after the company reported strong fourth-quarter financial results and offered an upbeat forecast for 2026. For the fourth quarter, Quest's revenue grew 7.1% year-on-year to $2.81 billion, surpassing analyst estimates. Its adjusted earnings of $2.42 per share also came in ahead of expectations. Looking forward, the company's full-year 2026 revenue guidance was a notable highlight, coming in",
    "url": "https://finnhub.io/api/news?id=54a232a6ec600abc731f54cb97f3f115e9c8d0937eb42722ba57f8efeb92de43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770755442,
      "headline": "Why Is Quest (DGX) Stock Soaring Today",
      "id": 139036504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX) jumped 6.8% in the afternoon session after the company reported strong fourth-quarter financial results and offered an upbeat forecast for 2026. For the fourth quarter, Quest's revenue grew 7.1% year-on-year to $2.81 billion, surpassing analyst estimates. Its adjusted earnings of $2.42 per share also came in ahead of expectations. Looking forward, the company's full-year 2026 revenue guidance was a notable highlight, coming in",
      "url": "https://finnhub.io/api/news?id=54a232a6ec600abc731f54cb97f3f115e9c8d0937eb42722ba57f8efeb92de43"
    }
  },
  {
    "ts": null,
    "headline": "What's going on in today's session: S&P500 movers",
    "summary": "Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.",
    "url": "https://finnhub.io/api/news?id=8b79d7db2b0791d0a64eccdd468dfdf1662f99b5e81038c5c0c798a7cb6daef2",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770753904,
      "headline": "What's going on in today's session: S&P500 movers",
      "id": 139035321,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "DGX",
      "source": "ChartMill",
      "summary": "Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.",
      "url": "https://finnhub.io/api/news?id=8b79d7db2b0791d0a64eccdd468dfdf1662f99b5e81038c5c0c798a7cb6daef2"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rallies To A High; Credo Explodes On Updated Outlook (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose Tuesday despite weaker-than-expected retail sales data. TSMC stock hit a high.",
    "url": "https://finnhub.io/api/news?id=c6577f3f17f813957f5a55e76a3fad668c69da52f8bbab28d6edce327cf4705b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770741182,
      "headline": "Stock Market Today: Dow Rallies To A High; Credo Explodes On Updated Outlook (Live Coverage)",
      "id": 139033453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose Tuesday despite weaker-than-expected retail sales data. TSMC stock hit a high.",
      "url": "https://finnhub.io/api/news?id=c6577f3f17f813957f5a55e76a3fad668c69da52f8bbab28d6edce327cf4705b"
    }
  },
  {
    "ts": null,
    "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.",
    "summary": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.",
    "url": "https://finnhub.io/api/news?id=bc8c548e502afc8ebb60e1ff7c0445a811521f5306e9819e4cb9a906b21a67e7",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770746702,
      "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.",
      "id": 139034018,
      "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
      "related": "DGX",
      "source": "ChartMill",
      "summary": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.",
      "url": "https://finnhub.io/api/news?id=bc8c548e502afc8ebb60e1ff7c0445a811521f5306e9819e4cb9a906b21a67e7"
    }
  },
  {
    "ts": null,
    "headline": "Stay informed with the top movers within the S&P500 index on Tuesday.",
    "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.",
    "url": "https://finnhub.io/api/news?id=23b2b9afcacd636e54e3d566f5e434aa79cf94d1845b87a89222e263aded5639",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770744907,
      "headline": "Stay informed with the top movers within the S&P500 index on Tuesday.",
      "id": 139033279,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "DGX",
      "source": "ChartMill",
      "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.",
      "url": "https://finnhub.io/api/news?id=23b2b9afcacd636e54e3d566f5e434aa79cf94d1845b87a89222e263aded5639"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics (DGX) Earnings Call Transcript",
    "summary": "With diligent execution of our strategy and a strong fourth quarter, we generated double-digit growth in revenues and earnings per share for the full year.  In 2025, we expanded our category-defining clinical innovation to meet robust demand, formed strategic collaborations with elite health care organizations, and further advanced our position as the premier lab engine powering the wellness industry.  As we look ahead to 2026, our guidance reflects our continued confidence in our business strengths and market fundamentals, which include favorable demographic trends, increasing use of blood-based lab diagnostics, and growing interest in preventative health and wellness.",
    "url": "https://finnhub.io/api/news?id=bf5f1e40ff529c0a7578f66d203585736f36433d6377a832a7045492ba8ea568",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770741063,
      "headline": "Quest Diagnostics (DGX) Earnings Call Transcript",
      "id": 139033769,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "With diligent execution of our strategy and a strong fourth quarter, we generated double-digit growth in revenues and earnings per share for the full year.  In 2025, we expanded our category-defining clinical innovation to meet robust demand, formed strategic collaborations with elite health care organizations, and further advanced our position as the premier lab engine powering the wellness industry.  As we look ahead to 2026, our guidance reflects our continued confidence in our business strengths and market fundamentals, which include favorable demographic trends, increasing use of blood-based lab diagnostics, and growing interest in preventative health and wellness.",
      "url": "https://finnhub.io/api/news?id=bf5f1e40ff529c0a7578f66d203585736f36433d6377a832a7045492ba8ea568"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up",
    "summary": "DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.",
    "url": "https://finnhub.io/api/news?id=ddecf1cf9797ba9499e999684a2cc4d35a9e82ff9b821b2f6ffde284532f01e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770738180,
      "headline": "Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up",
      "id": 139033770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.",
      "url": "https://finnhub.io/api/news?id=ddecf1cf9797ba9499e999684a2cc4d35a9e82ff9b821b2f6ffde284532f01e2"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates",
    "summary": "Quest Diagnostics (DGX) delivered earnings and revenue surprises of +2.85% and +2.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=b422c97cebb001f479297e6c6209805297a04c7a2902815ffd2860292467d989",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770728102,
      "headline": "Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates",
      "id": 139032173,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) delivered earnings and revenue surprises of +2.85% and +2.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=b422c97cebb001f479297e6c6209805297a04c7a2902815ffd2860292467d989"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Inc (NYSE:DGX) Beats Q4 Estimates, Announces Dividend Hike and $1B Buyback",
    "summary": "Quest Diagnostics beats Q4 2025 earnings estimates, announces a 7.5% dividend hike and a $1 billion share buyback boost.",
    "url": "https://finnhub.io/api/news?id=f09bbb70156e486e68a330d2586f0ebb1df91e87e199b511c861f7041bdd6c9d",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770726065,
      "headline": "Quest Diagnostics Inc (NYSE:DGX) Beats Q4 Estimates, Announces Dividend Hike and $1B Buyback",
      "id": 139028659,
      "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
      "related": "DGX",
      "source": "ChartMill",
      "summary": "Quest Diagnostics beats Q4 2025 earnings estimates, announces a 7.5% dividend hike and a $1 billion share buyback boost.",
      "url": "https://finnhub.io/api/news?id=f09bbb70156e486e68a330d2586f0ebb1df91e87e199b511c861f7041bdd6c9d"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript",
    "summary": "Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call February 10, 2026 8:30 AM ESTCompany ParticipantsShawn BevecJames Davis - Chairman, CEO &...",
    "url": "https://finnhub.io/api/news?id=41fad04681406646bc1a0e17ce8c972d4fd486475f49d63a5407696f291bae47",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770725661,
      "headline": "Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript",
      "id": 139032778,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call February 10, 2026 8:30 AM ESTCompany ParticipantsShawn BevecJames Davis - Chairman, CEO &...",
      "url": "https://finnhub.io/api/news?id=41fad04681406646bc1a0e17ce8c972d4fd486475f49d63a5407696f291bae47"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics: Q4 Earnings Snapshot",
    "summary": "The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $2.35 per share. The medical laboratory operator posted revenue of $2.81 billion in the period, also topping Street forecasts. Eight analysts surveyed by Zacks expected $2.75 billion.",
    "url": "https://finnhub.io/api/news?id=422e1349d07208f5acc292cb28bcde51bf1a35efa6c9670f90f97e39c4fa78e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770725173,
      "headline": "Quest Diagnostics: Q4 Earnings Snapshot",
      "id": 139030127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $2.35 per share. The medical laboratory operator posted revenue of $2.81 billion in the period, also topping Street forecasts. Eight analysts surveyed by Zacks expected $2.75 billion.",
      "url": "https://finnhub.io/api/news?id=422e1349d07208f5acc292cb28bcde51bf1a35efa6c9670f90f97e39c4fa78e7"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Incorporated 2025 Q4 - Results - Earnings Call Presentation",
    "summary": "Quest Diagnostics Incorporated 2025 Q4 - Results - Earnings Call Presentation",
    "url": "https://finnhub.io/api/news?id=2efd825d7fa31c5bea9408ff08bc050ba04ca0f006cedb852ad766c4b6e2736a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770724897,
      "headline": "Quest Diagnostics Incorporated 2025 Q4 - Results - Earnings Call Presentation",
      "id": 139032759,
      "image": "",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2efd825d7fa31c5bea9408ff08bc050ba04ca0f006cedb852ad766c4b6e2736a"
    }
  },
  {
    "ts": null,
    "headline": "Quest’s (NYSE:DGX) Q4 CY2025: Beats On Revenue",
    "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) announced better-than-expected revenue in Q4 CY2025, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=0156fc0d19da085feb93fa4655096d470d982859518e88f78b94f0a86bd9a980",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770724702,
      "headline": "Quest’s (NYSE:DGX) Q4 CY2025: Beats On Revenue",
      "id": 139030128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) announced better-than-expected revenue in Q4 CY2025, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=0156fc0d19da085feb93fa4655096d470d982859518e88f78b94f0a86bd9a980"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results;  Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share",
    "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.",
    "url": "https://finnhub.io/api/news?id=0649c9386881e5f8c2deb4c54feae1cd7340eb2cb2170bc135a258ef4a5c3320",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770724020,
      "headline": "Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results;  Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share",
      "id": 139028529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.",
      "url": "https://finnhub.io/api/news?id=0649c9386881e5f8c2deb4c54feae1cd7340eb2cb2170bc135a258ef4a5c3320"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization",
    "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share.",
    "url": "https://finnhub.io/api/news?id=c668890b6573ef863faa3fdc0f8e84a7b71c85551263cfda50e5fcffede6db67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770723180,
      "headline": "Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization",
      "id": 139028530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share.",
      "url": "https://finnhub.io/api/news?id=c668890b6573ef863faa3fdc0f8e84a7b71c85551263cfda50e5fcffede6db67"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics shares are trading higher after reporting better-than-expected Q4 financial results and FY26 outlook. Quest also raised its quarterly dividend and stock buyback.",
    "summary": "Quest Diagnostics shares are trading higher after reporting better-than-expected Q4 financial results and FY26 outlook. Quest also raised its quarterly dividend and stock buyback.",
    "url": "https://finnhub.io/api/news?id=94ab49c956399eb66855f04a6b923e734548759392c11c313da589f7669502d5",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770709913,
      "headline": "Quest Diagnostics shares are trading higher after reporting better-than-expected Q4 financial results and FY26 outlook. Quest also raised its quarterly dividend and stock buyback.",
      "id": 139029876,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=94ab49c956399eb66855f04a6b923e734548759392c11c313da589f7669502d5"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Sees FY2026 GAAP EPS $9.45-$9.65 vs $9.30 Est",
    "summary": "Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page",
    "url": "https://finnhub.io/api/news?id=45ed54f79227e33da33003485700b57c4e247f5da97d963b53b90e9f23a95658",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770709787,
      "headline": "Quest Diagnostics Sees FY2026 GAAP EPS $9.45-$9.65 vs $9.30 Est",
      "id": 139029877,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page",
      "url": "https://finnhub.io/api/news?id=45ed54f79227e33da33003485700b57c4e247f5da97d963b53b90e9f23a95658"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Sees FY2026 Adj EPS $10.50-$10.70 vs $10.43 Est; Sees Sales $11.700B-$11.820B vs $11.387B Est",
    "summary": "Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page",
    "url": "https://finnhub.io/api/news?id=f69203d0379fb006f4710da840bbb2fcd7d1118b0087c5c0ae862cac99fe0812",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770709755,
      "headline": "Quest Diagnostics Sees FY2026 Adj EPS $10.50-$10.70 vs $10.43 Est; Sees Sales $11.700B-$11.820B vs $11.387B Est",
      "id": 139029878,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page",
      "url": "https://finnhub.io/api/news?id=f69203d0379fb006f4710da840bbb2fcd7d1118b0087c5c0ae862cac99fe0812"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Breakdown: Quest Diagnostics Q4",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=0b58732135c294b708bd1bf6db6d6d3c71ed5cbcfacbb5149b9292a321d371cc",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770709686,
      "headline": "Earnings Breakdown: Quest Diagnostics Q4",
      "id": 139029879,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_5.jpg?width=2048&height=1536",
      "related": "DGX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=0b58732135c294b708bd1bf6db6d6d3c71ed5cbcfacbb5149b9292a321d371cc"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Q4 Adj. EPS $2.42 Beats $2.36 Estimate, Sales $2.806B Beat $2.754B Estimate",
    "summary": "Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.42 per share which beat the analyst consensus estimate of $2.36 by 2.54 percent. This is a 8.52 percent increase over earnings of $2.23 per share from the",
    "url": "https://finnhub.io/api/news?id=18081ec2cb77807bc8c9940725701c05f8426d3d2ac27781de9e9e384b858efe",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770709682,
      "headline": "Quest Diagnostics Q4 Adj. EPS $2.42 Beats $2.36 Estimate, Sales $2.806B Beat $2.754B Estimate",
      "id": 139029880,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.42 per share which beat the analyst consensus estimate of $2.36 by 2.54 percent. This is a 8.52 percent increase over earnings of $2.23 per share from the",
      "url": "https://finnhub.io/api/news?id=18081ec2cb77807bc8c9940725701c05f8426d3d2ac27781de9e9e384b858efe"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Increased Its Share Repurchase Authorization By $1B. The Increased Authority Is In Addition To The Approximately $0.4B That Was Available As Of December 31, 2025 Under The Company's Share Repurchase Program",
    "summary": "Quest Diagnostics Increased Its Share Repurchase Authorization By $1B. The Increased Authority Is In Addition To The Approximately $0.4B That Was Available As Of December 31, 2025 Under The Company's Share Repurchase Program",
    "url": "https://finnhub.io/api/news?id=8fc93931e59040546f8988474811849475fe7aa0ef06a82a3b39829ad4bc172c",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770708987,
      "headline": "Quest Diagnostics Increased Its Share Repurchase Authorization By $1B. The Increased Authority Is In Addition To The Approximately $0.4B That Was Available As Of December 31, 2025 Under The Company's Share Repurchase Program",
      "id": 139029881,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8fc93931e59040546f8988474811849475fe7aa0ef06a82a3b39829ad4bc172c"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Authorized 7.5% Increase In Its Quarterly Cash Dividend To $0.86/Share From $0.80/Share",
    "summary": "The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share.",
    "url": "https://finnhub.io/api/news?id=a23632985f769f5c4c4e0549dea5347d9d16e492f5f4a736c2909d89df6e4124",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770708903,
      "headline": "Quest Diagnostics Authorized 7.5% Increase In Its Quarterly Cash Dividend To $0.86/Share From $0.80/Share",
      "id": 139029882,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share.",
      "url": "https://finnhub.io/api/news?id=a23632985f769f5c4c4e0549dea5347d9d16e492f5f4a736c2909d89df6e4124"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Scheduled For February 10, 2026",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=34cdaa667719ebb868aab7df7cb89a13599504085c8554c65ca0fc74f16d2453",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770707478,
      "headline": "Earnings Scheduled For February 10, 2026",
      "id": 139029023,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
      "related": "DGX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=34cdaa667719ebb868aab7df7cb89a13599504085c8554c65ca0fc74f16d2453"
    }
  },
  {
    "ts": null,
    "headline": "The Great AI Squeeze: High Costs Take Center Stage In Hyperscalers' Earnings Reports",
    "summary": "The Great AI Squeeze: High Costs Take Center Stage In Hyperscalers' Earnings Reports",
    "url": "https://finnhub.io/api/news?id=b542bb582236d83bb0ccac76b39dac3a8d6d89d299263f31ac176f1df50ac620",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770701400,
      "headline": "The Great AI Squeeze: High Costs Take Center Stage In Hyperscalers' Earnings Reports",
      "id": 139028049,
      "image": "",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b542bb582236d83bb0ccac76b39dac3a8d6d89d299263f31ac176f1df50ac620"
    }
  }
]